BioPharm International integrates the global evolution in the research, development and

manufacture of biopharmaceutical products with the dynamic growth in the business

of biotechnology. We provide authoritative solutions to support the evolving scientific,

technical, business, regulatory, and legal challenges facing the biopharm community.

BioPharm International delivers a targeted audi-

ence of professionals involved in all stages of

the development and manufacture of biophar-

maceutical therapeutics and diagnostics.

*BPA June 2005^ Publisher’s Own Data

29,269bpa-QUALIFIED SUbSCRIbERS*

IN THE BUSINESS AND FUNCTIONS

YOU NEED TO REACHBusiness and industry ^

48.5% - Biopharmaceutical/Biologics, Classical Pharmaceutical Manufacturing (14,189)

9.1% - Biotechnology/Biopharmaceutical Research (2,667)

7.8% - Biopharmaceutical/Biologics, Biodiagnostic Process Development (2,269)

10.6% - Research Institutes, Universities and Colleges (3,121)

6.1% - Contract Research/Analytical Services (1,800)

3.2% - Specialty or Bulk Chemical Manufacturing, Bulk Products and Raw Materials Producers (901)

3.0% - Architecture/Engineering/Construction (879)

2.8% - Biodiagnostic Manufacturing (809)

2.7% - Biotherapeutic Discovery/Development/Transgenic Therapeutic Productions (781)

2.3% - Government (681)

2.1% - Business/Investment/Legal Services (612)

1.8% - Biopharmaceutical Formulation/Delivery (521)

Job function ^

27.6% - Research & Development (8,079)

18.5% - Quality Assurance/Control/Validation/Regulatory Affairs/Clinical Affairs (5,368)

14.5% - Corporate Management/Business Advisor (4,223)

8.9% - Production/Manufacturing (2,589)

7.4% - Process Development (2,166)

6.9% - Technology Transfer/Technical Services/Analytical Development/Support (2,049)

5.7% - Project Management (1,669)

6.3% - Lab Management (1,838)

3.3% - Plant Engineering/Facility Design (977)

0.9% - Materials Management/Purchasing/Procurement (270)

ABGENIXACAMBISACTELIONACTIVE BIOTECHADOLORAFFYMETRIXALEXIONALKERMESAMGENAMYLINANTIGENICSANTISOMAAPPLIED BIOSYSTEMSARADIGMARENAATHEROGENICSBASILEABERNA BIOTECHBIOGEN IDECBIOMARINBIOSITECAMBRIDGE ANTIBODYCANCERVAXCELERA GENOMICSCELGENECELL GENESYSCELL THERAPEUTICSCEPHALONCHIRONCORGENTECHCORIXACRUCELLCUBISTCURAGENCV THERAPEUTICSCYTOKINETICSDENDREONDIVERSAELANENZONEXELIXISEYETECHGENELOGICGENENTECHGENMABGEN-PROBEGENTAGENZYMEGILIADGUILFORD

HUMAN GENOMEICOSID BIOMEDICALIDENIXIDEXXINCYTEINNOGENETICSINTERMUNEINVITROGENISISKOSANLEXICONLIGANDMANNKINDMAXIMMAXYGENMEDAREXMEDIMMUNEMILLENNIUMMONSANTOMYOGENMYRIADNABINEKTARNEOPHARMNEOSENEUROCRINENEUROGENNPSNUVELOONYXOSIPAIN THERAPEUTICSPROGENICSPROTEIN DESIGN LABSQIAGENREGENERONRIGELSEATTLE GENETICSSERONOSYMYXTHERAVANCETRANSKARYOTICVASOGENVERNALISVERTEXVICALVICURONVIROLOGICXOMA

Reach the top public biotechcompanies*

BioPharm International delivers acccess to the top public

biotech companies as well as the industry’s top pharma-

ceutical companies that are heavily entrenched in bio-

pharmaceutical research & development.

*Parexel, Nature Biotechnology, June 2005**Publisher’s Own Data

and, the top phaRma companieswith an inteRest in biotechnology**

PFIZERWYETH

ABBOTTMERCK

JOHNSON & JOHNSON AMGEN

GLAXOSMITHKLINE ELI LILLY & CO.

SANOFI-AVENTIS HOFFMANN LA ROCHE

BRISTOL-MYERS SQUIBBSCHERING-PLOUGH

BAXTER BAYER

GENENTECHAKZO

ASTRA/ZENICAGENZYME

CARDINAL HEALTHBOEHRINGER

NOVARTIS BIOGEN IDEC

CHIRON DOW

HUMAN GENOME SCIENCES ALZA

BARR LABORATORIESJACOBS ENGINEERING

MEDAREX MEDIMMUNE

REGENERON TEVA

CAMBREX BIO SCIENCEWATSON

QUINTILES ALCON

PROCTER & GAMBLE 3M

BERLEX BIOSCIENCES IMCLONE

ALPHARMAIVAX DSM

GE HEALTHCARE AAIPPD

NOVO NORDISK TYCO

LONZA CEPHALONMILLIPOREALLERGAN

INVITROGEN

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . .

66856644640639539036435432529227826021420218915114714714314213313099968078777775757574737267666664616059575656555453535251515050

# of subscribers

Regulatory Beat – Jill Wechsler is a veteran editor stationed in Washington, where the news happens first. There, she gathers first hand knowledge of FDA, CBER, CDER and Congressional committee meet-ings information affecting the biopharmaceutical in-dustry such as regulatory decisions, policy develop-ments and trends. BioPharm is where she reports.

StreetTalk – Well-known author and expert business/financial commentator for CNN and Fox News, Brian J. O’Connell, offers the critical analyses of the industry’s key issues and strategies, companies and top executives, technology and trends from Wall Street.

Applications – Special guest authors from different companies in the US and abroad ex-pertly report in this column, which focuses on demonstrating to researchers, developers and manufacturers, new applications that affect the industry, whether it be in the lab or on the production line.

Outsourcing – Jim Miller, President of PharmSource Information Services, offers useful information to companies that uti-lize outsourcing services for IT, research, development, manufacturing, clinical tri-als, marketing or distribution or a mix-ture of these. In outsourcing, you’ll also find strategies, recent alliances, trend analyses and forecasting information.

Operations Excellence – If you’re looking to make your operations run more smooth-ly, look no further that Operations Excel-lence. This column focuses on improving operational efficiency based on real ex-periences. As an added bonus, quarterly reports from Tefen’s Amir London, share progress achieved by pharma and CMO members of the Operations Excellence Consortium, which meets on both the east and west coast of the US and in Europe.

Compliance Briefing – Biopharms and labs continually need to update processes, equip-

ment and documentation procedures due to the ever-changing regulations. There is al-ways something new on the horizon. Com-pliance Briefing’s rotating columnists provide the latest explanations of these changes and offer usable suggestions on how to comply.

BioPartnering – From a first hand perspec-tive, you’ll read about successful partner-ships and the rewards these companies reap. In areas such as R&D, manufacturing and clinical trials, business alliances can be beneficial. Learn from various industry ex-perts what to do and what not to do, here.

Law & Order – This new column, authored by six different legal authorities with exten-sive “field” experience in biopharma, ad-dresses some of the most important questions and concerns related to the research, devel-opment and production of biotherapeutics. Issues and recommendations relating to both the domestic and international arenas are provided in user-friendly terminology.

ROTATING COLUMNS

MONTHLY COLUMNSBioPharm International’s ed-

itorial staff prides itself on

delivering business critical

information directly af-

fecting every aspect of the

biopharmaceutical manu-

facturing industry. For

almost 20 years, industry

professionals have looked

upon BioPharm magazine

as an indispensable, edu-

cative source because it

is written by their peers,

the people working in the

industry, everyday. Put-

ting that much care and

concern into providing

accurate information can

only come from people in-

terested in advancing the

science of the business.

BioPharms’s year-at-a-glance department coverage for 2006:

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Editorial HigHligHts

JanuaryAd Close: December 2Materials Due: December 9

FebruaryAd Close: January 6Materials Due: January 13

MarchAd Close: February 3Materials Due: February 10

AprilAd Close: March 6Materials Due: March 13

MayAd Close: April 7Materials Due: April 14

JuneAd Close: May 5Materials Due: May 12

JulyAd Close: June 5Materials Due: June 12

AugustAd Close: July 10Materials Due: July 17

SeptemberAd Close: August 7Materials Due: August 14

OctoberAd Close: September 8Materials Due: September 15

NovemberAd Close: October 6Materials Due: October 13

DecemberAd Close: November 3Materials Due: November 10

• Separation/Purification, Chromatography• QA/QC/Validation• GMP• Compliance/Regulatory

• Contract Manufacturing/Outsourcing• GLP• Contamination Control• Analytical Methods

• Separation/Purification Chromatography • Fermentation & Cell Culture• Transgenics• Stability

• QA/QC/Validation• Contract Manufacturing/Outsourcing• GLP• Compliance/Regulatory

• Fermentation & Cell Culture• GMP• Contamination Control• Analytical Methods

• Separation/Purification, Chromatography• GLP• Trangenics• Protein Expression

• Fermentation & Cell Culture• Contract Manufacturing/Outsourcing• Stability • Analytical Methods

• QA/QC/Validation• GMP• Contamination Control• Compliance/Regulatory

• GLP• Transgenics• Protein Expression• Raising Capital

• Separation & Purification• QA/QC/Validation• Contract Manufacturing/Outsourcing• Drug Delivery

• Fermentation & Cell Culture • GMP• Contamination Control• Analytical Methods

• Transgenics• Compliance/Regulatory• Facility Management

issuE

• Facility Management • Raising Capital• Supply Chain Management • Bioinformatics

• Protein Expression• Legal Services• Facility Design/Expansion• Security

• Formulation Fill & Finish• Licensing/Partnerships• Supply Chain Management

• Facility Management• Legal Services• Raising Capital• Risk Management

• Drug Delivery• Licensing/Partnerships• Facility Design/Expansion• Bioinformatics

• Raising Capital• Supply Chain Management• Security

• Formulation Fill & Finish• Facility Management• Legal Services

• Licensing/Partnerships• Facility Design/Expansion• Bioinformatics

• Supply Chain Management• Security• Risk Management

• Formulation, Fill & Finish• Legal Services• Facility Design/Expansion

• Protein Expression• Licensing/Partnerships• Bioinformatics

2006 Annual Buyers’ Guide & DirectoryAd Close: July 10Materials Due: July 17

The most comprehensive guide to products, services and information pub-lished for the biopharmaceutical industry.

I N T E R N A T I O N A L

• A Guide to Protein Expression

• A Guide to Fermentation & Cell Culture

• A Guide to Separation & Purification

• A Guide to Global Compliance• Annual Buyers Guide & Directory

• A Guide to Advances in Bioprocessing• BioPartnerships – Strategic Alliances to Accelerate Drug Development

Value-added OppOrtunities

• Purchase Intelligence Lead Report• 4/C Release/Web Page Showcase

• Filtration/Purification User Survey• 4/C Release/Web Page Showcase

• Purchase Intelligence Lead Report• 4/C Release/Web Page Showcase

• 4/C Release/Web Page Showcase

• Purchase Intelligence Lead Report• 4/C Release/Web Page Showcase

• Contract Manufacturing User Survey• 4/C Release/Web Page Showcase

• Purchase Intelligence Lead Report• 4/C Release/Web Page Showcase

• Readex Ad Performance Study• 4/C Release/Web Page Showcase

• Purchase Intelligence Lead Report• 4/C Release/Web Page Showcase

• Fermentation & Cell Culture User Survey• 4/C Release/Web Page Showcase

• Purchase Intelligence Lead Report• 4/C Release/Web Page Showcase

• Application Notes Page• Corporate Capabilities Page

supplementBOnus distriButiOn

• Pep Talk

• Pittcon• Informex

• BIO 2006• INTERPHEX

• PDA

• Biologic Europe• DIA• AAPS

• AAPS• National Biotechnology Conference• Biologic USA

The Buyers’ Guide will be distrib-uted at all industry events attended from 9/06-8/07

• Display Ads• Highlighted Listings• Logos• Application Notes

• Online eDirectory ads

I N T E R N A T I O N A L

Digital data is required for all ad submissions. Preferred

format is PDF/X-1. Acceptable format is a hi-res PDF. Files

should be press optimized, converted to CMYK, and have

all fonts embedded. BioPharm International will be relieved

of all responsibility for any form of compensation if an ad is

supplied in non-preferred or non-acceptable formats, such

as native application files. Non-preferred or non-accept-

able formats will be charged a $150 processing fee. We

cannot guarantee the accuracy of reproduction from any

ads supplied in non-preferred or non-acceptable formats.

For detailed instructions of preferred formats, contact the

production manager or download digital ad specifications

from www.advanstar.com/adspec/.

BioPharm International will not supply a faxed or soft proof

on client-supplied files. We assume due diligence has been

taken by the client or by their agency to preflight and proof

all advertisements prior to submission.

Files may be submitted on CD-ROM. Files may also be

submitted to our FTP site. Please contact the production

manager for instructions.

To insure that your ad is reproduced correctly, a SWOP-cer-

tified color proof that has been made from the same file that

you supply to us must be provided. We cannot guarantee

the accuracy of reproduction of your ad without a SWOP

proof. No make-goods will be issued on ads that run with-

out a SWOP proof.

Digital Ad Requirements

Full Page

2/3 Page

1/2 Page

1/3 Page

1/4 Page

2006 Black & White Gross rates - Us Dollars

6,030

4,770

4,400

3,030

2,325

1x

5,630

4,500

4,090

2,865

2,205

3x

5,470

4,415

3,975

2,805

2,140

6x

5,130

4,190

3,740

2,605

1,995

12x

4,965

4,070

3,605

2,570

1,995

18x

4,845

3,960

3,524

2,540

1,930

24x

aD Dimensions

Full Page

2/3 Page

1/2 Page Island

1/2 Page Horizontal

1/2 Page Vertical

1/3 Page Square

1/3 Page Vertical

1/4 Page

6 3/4”

4 1/2”

4 1/2”

6 3/4”

3 3/8”

4 1/2”

2 1/8”

3 3/8”

Width

9 1/2”

9 1/2”

7”

4 5/8”

9 1/2”

4 5/8”

9 1/2”

4 5/8”

Depth

Trim Size

Bleed

Live Matter

Spread Size

Bleed (Spread)

7 3/4”

8”

7”

14 1/2”

15 3/4”

Width

10 1/2”

10 3/4”

9 3/4”

9 1/2”

10 3/4”

Depth

special positions- Us Dollars

Cover 2

Cover 3

Cover 4

Preferred Position

680

650

890

530

color charGes- Us Dollars

Standard

Matched

Metallic

Four-Color

750

885

1,100

1,840

Send all materials and ad insertion orders to:

Rhonda Rychlak, BioPharm International,131 West 1st Street, Duluth, MN 55802-2065

Tel: 1-218-723-9372 Fax: 1-218-723-9223Email: rrychlak@advanstar.com

Full Page

2/3 Page

1/2 Page

1/3 Page

1/4 Page

2006 FoUr color Gross rates - Us Dollars

7,870

6,610

6,240

4,870

4,165

1x

7,470

6,340

5,930

4,705

4,045

3x

7,310

6,255

5,815

4,645

3,980

6x

6,970

6,030

5,580

4,445

3,835

12x

6,805

5,910

5,445

4,410

3,835

18x

6,685

5,800

5,365

4,380

3,770

24x

primers

Trim Size

Bleed

Live Matter

Spread

Bleed (Spread)

5 1/4”

5 1/2”

4 1/4”

10 1/2”

11”

8 3/8”

8 5/8”

7 3/8”

8 3/8”

8 5/8”

DepthWidth

I N T E R N A T I O N A L

Digital data is required for all ad submissions. Preferred

format is PDF/X-1. Acceptable format is a hi-res PDF. Files

should be press optimized, converted to CMYK, and have

all fonts embedded. BioPharm International will be relieved

of all responsibility for any form of compensation if an ad is

supplied in non-preferred or non-acceptable formats, such

as native application files. Non-preferred or non-accept-

able formats will be charged a $150 processing fee. We

cannot guarantee the accuracy of reproduction from any

ads supplied in non-preferred or non-acceptable formats.

For detailed instructions of preferred formats, contact the

production manager or download digital ad specifications

from www.advanstar.com/adspec/.

BioPharm International will not supply a faxed or soft proof

on client-supplied files. We assume due diligence has been

taken by the client or by their agency to preflight and proof

all advertisements prior to submission.

Files may be submitted on CD-ROM. Files may also be

submitted to our FTP site. Please contact the production

manager for instructions.

To insure that your ad is reproduced correctly, a SWOP-cer-

tified color proof that has been made from the same file that

you supply to us must be provided. We cannot guarantee

the accuracy of reproduction of your ad without a SWOP

proof. No make-goods will be issued on ads that run with-

out a SWOP proof.

Digital Ad Requirements

Full Page

2/3 Page

1/2 Page

1/3 Page

1/4 Page

2006 Black & White Gross rates - euro

5,007

3,960

3,653

2,516

1,930

1x

4,674

3,736

3,396

2,379

1,831

3x

4,542

3,666

3,300

2,329

1,777

6x

4,259

3,479

3,105

2,163

1,656

12x

4,112

3,379

2,993

2,134

1,656

18x

4,023

3,288

2,927

2,109

1,602

24x

ad dimensions

Full Page

2/3 Page

1/2 Page Island

1/2 Page Horizontal

1/2 Page Vertical

1/3 Page Square

1/3 Page Vertical

1/4 Page

171 mm

114 mm

114 mm

171 mm

85mm

114 mm

54 mm

85 mm

Width

241 mm

241 mm

178 mm

117 mm

241 mm

117 mm

241 mm

117 mm

Depth

Trim Size

Bleed

Live Matter

Spread Size

Bleed (Spread)

197 mm

203 mm

178 mm

368 mm

400 mm

Width

267 mm

273 mm

248 mm

241 mm

273 mm

Depth

special positions- euro

Cover 2

Cover 3

Cover 4

Preferred Position

565

540

739

440

color charGes- euro

Standard

Matched

Metallic

Four-Color

623

735

913

1,528

Send all materials and ad insertion orders to:

Rhonda Rychlak, BioPharm International,131 West 1st Street, Duluth, MN 55802-2065

Tel: 1-218-723-9372 Fax: 1-218-723-9223Email: rrychlak@advanstar.com

Full Page

2/3 Page

1/2 Page

1/3 Page

1/4 Page

2006 Four color Gross rates - euro

6,534

5,488

5,181

4,043

3,458

1x

6,202

5,264

4,924

3,906

3,358

3x

6,069

5,193

4,828

3,857

3,305

6x

5,787

5,007

4,633

3,691

3,184

12x

5,650

4,907

4,521

3,662

3,184

18x

5,550

4,816

4,454

3,637

3,130

24x

primers

Trim Size

Bleed

Live Matter

Spread

Bleed (Spread)

133 mm

140 mm

108 mm

267 mm

279 mm

212 mm

219 mm

187 mm

212 mm

219 mm

DepthWidth

I N T E R N A T I O N A L

Benefits to advertisers participating in the purchase intelligence program:• List includes only qualified leads.• These high-quality leads are interested in purchasing the product or service you’re selling within the next six months.• Leads include detail of products and services of interest and all demographic and contact information.• This is an opportunity to “strike while the iron is hot” and turn these leads into active customers!

lead categories and suBcategories:• Biochemicals, Chemicals & Raw Materials• Contract Pharmaceutical Services & Consulting• Processing Equipment & Manufacturing Systems• Laboratory Products & Equipment• Separation & Purification• Fermentation & Cell Culture Products• Information Technology• Controlled Environments

As a Value-added Opportu-

nity, BioPharm International

designates six issues each

year on which to conduct

Purchase Intention studies

among our subscribers. Via

telephone interviews, we

uncover active buyers from

our qualified circulation.

We ask specific questions

regarding upcoming spend-

ing for various products and

services over the next three

to six months. Within 48

hours of the completion of

the interviews, frequency

advertisers receive their cat-

egory specific leads in hard

copy and electronic format.

To proactively generate qualified leads, contact:

Pat Venezia732-346-3011

pvenezia@advanstar.com

Mike Wilson847-441-3720

mwilson@advanstar.com

You need qualified buyers within your target market.

BioPharm International’s Purchase Intelligence Program PROVIDES THEM FREE!

Purchase Intelligence

Integrated Marketing

Display Advertising—as the foundation of any b-to-b marketing program display ads allow you to touch 29,269 BPA-qualified readers* with your brand or mar-keting message. Build on the impact your ad makes by utilizing other channels to further reinforce your message.

Custom Publishing—work with us to write and design a custom white paper or article published as an advertorial. Material for this white paper can be gathered from events such as a reader roundtable or Webinar offered by BioPharm and delivered through print, email and web-based channels that incorporate lead generation mecha-nisms.

Inserts—offer a unique way to deliver white papers, brochures or any other collateral material to our readers.

Polybag—you can’t get better placement than being specially packaged with the issue! Send your message as a ride-along and readers will get the message as soon as the issue hits their desk.

Direct Mail—rent our list to ensure your material hits your most important audience.

Post-It-Notes—Post-It-Notes serve as front cover reminders about your brand. Use them to call out your ads in the issue or run a series of 6 or 12 Post-It-Notes for a truly unique campaign.

Business Reply Cards—serve as an efficient and effective direct response medium. BRC’s can be used to promote a contest or simply provide readers with a distinct opportunity to contact you for more information.

PRINT-BASED MARKETINGBioPharm offers pharma and biopharm manu-

facturing companies multiple channels with

which to reach a highly reputable audience. To

make the most of your marketing efforts, gain

the greatest access to this group by allowing us

to set up your personalized program.

I N T E R N A T I O N A L

Conferences—Advanstar’s Pharmaceutical &

Science Group conferences provide top indus-

try gatherings for up-to-the-minute information

and unmatched opportunity to interact with

biopharm/pharmacetutical industry executives.

Under this umbrella, the Institute for Valida-

tion Technology (IVT) and Pharmaceutical Ex-

ecutive produced successful conferences on a

variety of topics relevant to your market. Ask

your rep how you can leverage your sponsor-

ship budget at one of our 2006 conferences.

Single Sponsored Events—do you have an idea for

a conference but lack the resources to bring your

target community together? Partner with us to

launch a conference focused on your objectives.

Reader Roundtables—you provide the topic

and we provide a roundtable of readers, se-

lected based on your target demographic, and

a facilitator to moderate your meeting. Think

of it as your very own expert focus group.

FAcE-To-FAcE MARKETING

*BPA June 2005

Web Site—there are many traditional and innovative opportunities available on biopharminternational.com including banner, button, skyscraper and big-box advertising, product spotlights, agency spotlights and QuickPolls that provide unique ways for sellers to connect with buyers.

Webinar—work with us to create an online event that will help you address vital industry issues with the people who are key to the industry.

E-mmercials—capture the attention of readers with this exciting flash presentation tool. Deliver your e-mmercial via a tar-geted email, post it on our site, and use it on your own site, in sales calls and at your trade show booth.

MarketPulse—allow us to deliver the answers to your most pressing questions with a customized on-line survey among our readers.

ProductBlast—Blast your product offerings, on-line catalog or announce your newest products with ProductBlast. Sent to 5,000 subscribers, based on your demographic selects, ProductBlast is an effective way to spread the word about your prod-ucts, and directly link readers to them.

E-Newsletter—this content-driven newsletter will offer a unique opportunity to surround your advertisement with content relevant to your brand, and route buyers to a page on your site specific to your message.

E-nterviews—extend your trade show message! You provide a spokesperson to deliver your product message and we’ll pro-vide the camera crew, edit the footage and produce a 5-minute video for email distribution the next morning, to readers in your demographic selects. The video is available via links in the email and on the web site.

E-Show Dailies—deliver news from your conference or trade show to thousands in your industry even if they’re not at the event. We’ll send a reporter to cover your conference who will produce an e-show daily. An email will be pushed the next morning, to readers in your demographic selects, and available on the site with links directing users to show coverage.

web-based marketing

I N T E R N A T I O N A L

SupplementS

Buyers’ Guide & DirectoryPublished in September

The BioPharm International Buyers’ Guide and Directory is a popular annual resource that offers buyers and sellers a com-fortable forum in which to meet

to conduct business. Manufacturers and developers looking for products, suppliers and partners to help them produce new drugs can find service providers offering such in this publication. The Buyers’ Guide offers a variety of advertising options to fit your specific marketing budget including display ads, en-hanced listings, strategic logo placement and even a special section dedicated to application notes.

The popularity of this special issue has prompted BioPharm to introduce an online version to accom-pany the print directory. The BioPharm eDirectory, introduced last year, has grown significantly and has proven to be a valued asset among the biopharma-ceutical manufacturing and supplier community. Various packages as well as traditional web advertis-ing suited to reinforce and extend your marketing message are available.

BioPartnerships: Strategic Alliances to Accelerate Drug DevelopmentPublished in October

BioPharm International and its sis-ter publication, PharmaceuticalExecutive, team up each year to

produce this highly regarded industry resource fo-cusing on partnering. Partnerships, in many cases, are what allow safe, effective drugs to get to market because of the old adage that we can’t do everything. Some companies prefer to focus on a piece of the puzzle. This resource offers pharma execs the in-sight they need to foster successful relationships with suitable business partners and information on how to keep those relationships sound and profitable.

primerSBiopharm International’s highly regarded Primers serve to quickly up-date and educate professionals on the latest, most significant develop-ments in the industry. The 2006 “Guide To” Series will provide, both, an introduction to, as well as timely information and discussion of, the trends and new developments in specific areas of interest and will prove, once again, to be essential resources, distributed and frequent-ly referenced often throughout the biopharmaceutical community.

The Guide to Protein ExpressionFebruary – New: First time offered

Industry professionals and novices alike will find this guide valuable because it summarizes both traditional and not-so-traditional pro-tein expression technology: mammalian, viral, yeast and bacterial to plants, animals and insects – for functional analysis and other ap-plications. This new primer also includes solutions for enhancement, optimization, modification, toxic removal and scale-up of these ex-pression systems. Industry luminaries share what the future may hold for protein expression.

The Guide to Fermentation & Cell Culture (INTERPHEX ISSUE)March – An Update to the March 2003 Guide

Learn about the science that supports fermentation and cell culture and the advances in processes and applications that have emerged since the 2003 guide was published. An updated glossary and a new list of refer-ences and resources will make this an important addition to your library.

The Guide to Separation & PurificationJune – An Update to the December 2000 Guide

Read about the theory, processes, technology and validation of sepa-ration and purification. Issues of concern, as well as possible solutions – authored by the some of the most knowledgeable industry experts – are presented, along with an updated glossary and resource lists.

The Guide to Global ComplianceSeptember – New: First time offered

There are multiple compliance challenges for biopharma-ceutical companies throughout the world. This primer of-fers an overview of the similarities and differences in regula-tory requirements among the countries most involved in the development and manufacture of biotherapeutics, as well as the most recent progress in reaching international harmonization.

The Guide to Advances in Bioprocessing October – New: First time offered

Building upon the fundamentals of bioprocessing, this guide offers a comprehensive look at the most up-to-date technology currently in use, as well what is in the pipeline, and the likely impact both will have on the industry. Particular attention is given to the solutions and strategies that will improve downstream processing performance.

Special Issues

Purchase Authority

I N T E R N A T I O N A L

32% of readers are involved in purchasing manufacturing/processing equipment & products.

25.7% - Chromatographic Equipment

23.8% - Separation & Purification Products

22.2% - Filters, Membranes & Air Purifiers

20.1% - Centrifuge Products

6.1% - Magnetic Sorting Systems & Particles

54% of readers are involved in purchasing laboratory products and equipment.

34.3% - Analytical Laboratory Equipment

25.0% - Calibration Standards21.5% - Glassware & Pipettes

21.3% - Laboratory Appliances

19.2% - Cleaning Equipment, Autoclaves & Ovens

18.0% - Liquid Handling Equipment & Pumps18.7%- Incubators

17.8% - Electrophoresis Products & Apparatus

17.1% - Spectroscopy Equipment15.2% - Safety

14.3% - Measuring Devices12.9% - Lyophilizers

10.7% - Homogenizers

9.1% - DNA & RNA Analysis

6.3% - Nuclear & Luninescence Insturmentation & Accessories5.1% - Combinatorial Chemisty & Hi-Throughput Screening

38.3% of readers are involved in purchasing separation & purification products & services.

18.7% - Processing Equipment

16.1% - Bio Reactors/Fermentors

14.3% - Disposable Processing Equipment

13.1% - Fill & Finish

11.7% - Packaging & Labeling Equipment

11.4% - Storage Equipment & Distribution

51.2% of readers are involved in purchasing biochemicals, chemicals and raw materials.

26.6% - Reagents

26.4% - Chemicals

25.5% - Raw Materials

22.0% - Solvents, Detergents & Buffers

21.7% - Biochemicals & Organic Raw Materials

20.6% - Proteins & Peptides

19.4% - Antibodies & Antigens

17.5% - Contract Consulting & Pharmaceutical Services

17.5% - Specialty or Bulk Raw Materials

16.1% - Enzymes

14.7% - Media & Sera

10.3% - Viruses & Bacteria

9.8% - Enzymes

26.4% of readers are involved in purchasing products for controlled environments.

13.1% - Clean Room Supplies

11.9% - Clean Room Garments

11.0% - Clean Room Components & Design

11.0% - Hoods & Ventilation

9.1% - Cleaning Validation Assays

9.1% - Air Samples

36.2% of readers are involved in purchasing outsourced and pharma services.

17.5% - Contract Manufacturing

17.3% - Analytical Methods & Validation Services

16.8% - Contract Laboratory

15.7% - Biopharm Development & Scale-Up

13.1% - Contract Consulting

12.1% - Contract Research

7.2% - Drug Discovery & Lead Optimization

27.6% of readers are involved in purchasing computer systems.

15.4% - Software Systems & Accessories

13.1% - Validation Software

12.4% - Data Management Software

11.4% - Hardware Systems & Accessories

11.0% - Documentation Software

8.6% - Bioprocess Control Software

8.4% - Automation & Robotics

6.1% - Batch Control Software

24.1% of readers are involved in purchasing fermentation and cell culture products and equipment.

16.4% - Cell Culture

16.4% - Cell Culture Equipment

14.3% - Fermentation

9.6% - Fermentation & Cell Culture Products

9.6% - Cryogenics

3.7% - Plant Transgenics

14.7% of readers are involved in purchasing engineering facilities services.

11.0% - Utilities & Waste Management

10.7% - Engineering & Facilities Services

8.4% - Facilities Design & Construction

2004 Readership Study Conducted by Proximity Research

93.7% of readers have taken action in response to ads and articles in BioPharm International.

74.5% - Filed for future reference74.1% - Discussed with others

59.6% - Routed an ad/article to another person

34.3% - Incorporated new technique/medium/product33.9% - Recommended the purchase of a product/service

25.0% - Called or wrote for more information

21.5% - Purchased a product or service

With an additional 1.72 readers per copy, Bio-

Pharm International’s total audience is over

79,612. These loyal industry decision makers

provide an excellent audience for which to

market your products and services.

I N T E R N A T I O N A L

^ Biopharm related industries: Biopharmaceutical, Biologics Process Development (23.8%), Conventional Pharma Manufacturing (19.6%), Biodiagnostic Process De-velopment (0.9%), Biodiagnostic Manufacturing (2.3%), Biotherapeutic Discovery/Development (2.1%), Biopharmaceutical Formulation/Delivery (5.8%), Transgenic Therapeutic Productions (0.2%), Specialty or Bulk Chemical Manufacturing, Bulk Products, Raw Material Producers (2.8%), Biotechnology/Biopharm Research (12.1%)

On average, subscribers spend forty-seven minutes reading each issue.

- One hour or more

- Forty-five minutes to One Hour

- Thirty to Forty-five minutes

- Less than Thirty minutes

- No Answer

11.2%

35.5%

23.6%

29.4%

0.2%

More than three-quarters of subscribers spend time reading and looking through 3 or 4 of the last 4 issues received.

- Four of the last four issues

- Three of the last four issues

- Two of the last four issues

- Recent subscriber, have not yet received

four issues

- One of the last four issues

- None of the last four issues

- No answer

61.9%

15.0%

12.4%

7.0%

2.6%

0.9%

0.2%

Primary business functions of companies BioPharm readers work for.

- BioPharm/Biotech/Pharma-related Industries ^

- University/College/Research Institute

- Contract Research & Analytical Services

- Business/Investment/Legal Services

- Architecture/Engineering/Construction

- Government

- Other

- No Answer

70.6%

6.5%

4.0%

3.0%

2.8%

1.2%

9.6%

2.3%

54.2% of BioPharm readers are in management positions.

- Manager

- Scientist

- Director

- Corporate or Executive

Management

- Engineer

- Staff/Associate

- Other

- Chemist

- No Answer

24.5%

18.5%

16.6%

13.1%

8.9%

6.8%

5.6%

4.2%

1.9%

On average, readers work for companies with an annual revenue of $1.8 billion.

- More than $1 Billion

- $500 - $999M

- $100 - $500M

- $1 - $99M

- $250 - $999k

- Less than $250k

- No Answer

16.8%

12.4%

10.5%

26.6%

5.8%

15.4%

12.4%

Most BioPharm readers perform func-tions in QA/QC/Validation, Research or Process Development.

- QA/QC/Validation

- Research

- Process Development

- Production Manufacturing

- Corporate Management

- Project Management

- Technical Services/Analytical Support

- Regulatory Affairs/Clinical Affairs

- Lab Management

- Business Advisor

- Technology Transfer

- Other

- No Answer

- Engineering/Design

23.1%

16.8%

13.8%

7.7%

7.5%

6.3%

4.7%

4.4%

4.2%

3.3%

3.0%

2.3%

1.6%

1.2%

Readership

If subscribers could only receive 1 industry publication, most would choose BioPharm International.

55.1% - BioPharm International

9.1% - Genetic Engineering News

5.4% - BioProcess International6.3% - Contract Pharma

1.4% - Bio IT World1.9% - Bioprocessing Journal

4.0% - Bioscience4.2% - BioTechniques

8.2% - Nature Biotechnology

4.4% - No Answer

Areas of interest to BioPharm Internationalreaders.

76.2% - Biochemicals, Chemicals, Raw Materials

72.0% - Laboratory Products & Equipment64.1% - Contract Consulting & Pharmaceutical Services

52.3% - Separation & Purification

50.0% - Processing Equipment/Manufacturing Systems43.7% - Controlled Environments

39.0% - Fermentation & Cell Culture28.3% - Engineering Facilities

52.3% - Computer Systems

Reasons why subscribers choose BioPharm Internationalover all other industry related publications:

83.6% - It keeps me up-to-date on the latest advances and industry trends

60.0% - It gives me information that helps me do my job better48.1% - It provides technically accurate information

41.1% - It helps me identify potential suppliers/resources and make purchasing decisions

0.5% - No Answer

40.0% - I am interested in international growth and trends

Questionnaires were emailed to a sample of 5,000 subscribers from BioPharm International’s subscriber file. Names were selected randomly on an nth name basis, in accordance with demographic breakouts, from active, qualified subscribers who have requested the publication.Proximity Research, an independent company specializing in research, circulation and email campaign management for b2b publishers, located in Cleveland Ohio, developed the electronic survey, deployed the emails and tabulated the results.The electronic questionnaire asked about reader preferences, the readability utility of BioPharm International and how readers used the information gained from reading BioPharm International in their job.Proximity sent an initial effort of 5,000 emails. 4,496 emails were delivered for a delivery rate of 89.8%. A total of 35 respondents opted-out and 594 emails bounced. The survey netted 428 responses for a response rate of 9.52%. An incentive of a randomly awarded digital camera was offered in both invitation emails.The level of confidence for this survey is (+/- 5%).

Survey Methodology

Nearly one-third of BioPharm Internationalreaders cannot be reached in ANY of the following industry related publications:

28.7% - Genetic Engineering News

28.3% - BioProcess International

26.4% - Contract Pharma

25.9% - BioTechniques

15.2% - Bioprocessing Journal

14.3% - Bio IT World

11.9% - Nature Biotechnology

11.2% - Bioscience

29.4% - None

2004 Readership Study Conducted by Proximity Research

Are BioPharm International readers in-volved in R&D?

- Yes

- No

- No Answer

58.6%

39.3%

2.1%

On average, readers work for companies investing $302.9 million in R&D.

- More than $1 Billion

- $500 - $999M

- $100 - $500M

- $1 - $99M

- $250 - $999k

- Less than $250k

- No Answer

6.5%

5.6%

12.4%

25.5%

11.0%

21.5%

17.5%

On average, 69.7% of BioPharm readers’ research is geared towards commercial product development.

- 100%

- 75-99%

- 50-74%

- 25-49%

- Less than 25%

- No Answer

29.1%

25.1%

19.1%

12.0%

13.5%

1.2%

Standard termS and ConditionS for advertiSing

The following terms and conditions (the “Standard Terms”) shall be incorporated by reference into all Insertion Orders submitted to Advanstar Communications Inc. (“Publisher”) by Advertiser or its advertising agency:

A – Invoices are rendered at date of publication.

B – Publisher holds the Advertiser and its advertising agency jointly responsible for paying all duly authorized advertising inserted in or attached to BioPharm International. All past due payments may be reinvoiced directly to the

Advertiser, who will be held fully responsible for payment.

C – Terms: Invoices are rendered on the publication date of each issue and are due upon receipt. Agency commission will be disallowed on all past due invoices. In the event Advertiser’s account is placed for collection, Advertiser

and agency agree to pay Publisher for all reasonable collection costs and/or attorneys’ fees incurred. Advertiser and agency also agree to pay finance charges on the unpaid account balance at the rate of 1-1/2% per month or the

maximum permitted by law.

D – Publisher will not be bound by any terms, conditions or provisions appearing on insertion orders or copy instructions which conflict with provisions of these Standard Terms, including, without limitation, sequential liability state-

ments from advertising agencies. In the event of any inconsistency between an insertion order and/or copy instructions and these Standard Terms, the Standard Terms shall control.

E – All advertisements are accepted and published by the Publisher on the representation that the agency and/or Advertiser are properly authorized to publish the entire contents and subject matter thereof.

F – Advertiser hereby grants Publisher the right and license to use, reproduce, transmit, and distribute all creative materials supplied by or on behalf of Advertiser, including without limitation, all text, graphics, illustrations and

photographs (the “Creative”). Advertiser represents and warrants that: (i) it has all the necessary rights in the Creative; (ii) the Creative does not violate any applicable law or regulation; and (iii) the Creative does not violate or infringe

upon any third party right in any manner or contain any material or information that is defamatory, libelous, slanderous, that violates any person’s right of publicity, privacy or personality, or may otherwise result in any tort, injury,

damage or harm to any person. Advertiser acknowledges that Publisher is relying on the foregoing representations and warranties. Advertiser agrees to indemnify, defend and hold Publisher and its affiliates, and their respective

officers, directors and employees, harmless from and against any and all expenses and losses of any kind (including reasonable attorneys’ fees and costs) incurred based upon a breach of any of the foregoing representations and

warranties or in connection with any claim arising from or related to any advertisement supplied by Advertiser or its agents and run by Publisher.

G – Publisher reserves the right to reject any advertising which Publisher feels is not in keeping with the publication’s standards or for any other reason, even if the advertising has been published previously by Publisher.

H – Publisher shall not be liable for any omitted, misplaced, or mispositioned advertisements.

I – All orders are accepted by Publisher subject to change in rate upon notice from Publisher.

J – Orders may be cancelled within ten (10) business days of the effective date of a change of rates without incurring a shortrate adjustment, provided the Advertiser’s contract rate has been earned as of the date of cancellation.

K –An order may be cancelled without liability up to thirty (30) days prior to the issue’s ad close date. Publisher reserves the right to demand payment for orders cancelled less than thirty (30) days prior to ad close, regardless of the

date of ad placement.

L – A 1/4 page ad is the minimum rate holder.

M – Advertiser will be shortrated if, within a 12-month period from the date of the first insertion, Advertiser does not use the amount of space upon which its billings has been based. Advertiser will be rebated if, within a 12-month

period from the date of the first insertion, Advertiser has used sufficient additional space to warrant a lower rate than that at which it has been billed.

N – Costs incurred by Publisher for production work on advertisements will be charged to the Advertiser regardless of whether or not the ad runs. Advertiser will be charged for any artwork, separations, halftone, shipping, or typog-

raphy provided by Publisher.

O – In the event a change of copy is not received by Publisher by the publication’s ad closing date, the copy run in the previous issue of the publication will be inserted.

P – Publisher will hold Advertiser’s materials for a maximum of one year from last issue date. It is the responsibility of the Advertiser to arrange for the disposition of artwork, proofs or digital materials prior to that time, otherwise

materials will be destroyed. All requests must be submitted in writing.

Q – Publisher will not be held responsible for consequential costs or other damages due to loss or damage of digital ad materials, art, proofs or transparencies.

R – Reader response inquiries are provided as a service. Publisher disclaims all liability and responsibility for inaccuracies.

S – Under no circumstances shall Publisher be liable for any indirect, incidental, special or consequential damages (including, without limitation, loss of profit or impairment of goodwill) of any Advertiser. Under no circumstances

shall Publisher’s direct or indirect liability to any advertising agency or Advertiser exceed the invoiced cost of the advertisement. Notwithstanding the foregoing, Publisher shall have no liability for (i) any failure or delay resulting from

conditions beyond Publisher’s control; or (ii) errors in content or omissions in any creative or advertising materials provided by Advertiser.

T - These Standard Terms, together with insertion orders submitted by Advertiser, (i) shall be governed by and construed in accordance with the laws of the State of New York and the United States, without giving effect to principles

of conflicts law; (ii) may be amended only by written agreement executed by an authorized representative of each party; and (iii) constitute the complete and entire expression of the agreement between the parties, and shall super-

sede any and all other agreements regarding the subject matter hereof, whether written or oral, between the parties. Failure by either party to enforce any provision of these Standard Terms shall not be deemed a waiver of future

enforcement of that or any other provision. Advertiser may not resell, assign, or transfer any of its rights hereunder.

CommiSSion

Accredited advertising agencies receive a 15% commission provided invoices are paid within 30 days.

Production charges are not subject to agency commission.

Contact us at 1-888-468-8162